By Julia Karow

This article was originally published Jan. 12.

Illumina's human genome sequencing services group has about 1,000 genomes on order, including one order for several hundred genomes from a "major pharmaceutical company," according to a company executive. In addition, Illumina plans to introduce a rare-cell capture and sequencing service this spring for analyzing circulating tumor cells and fetal cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.